期刊文献+

法舒地尔对冠脉内皮细胞的保护作用

The Protective Effect of Fasudil on Coronary Endothelial Cells
下载PDF
导出
摘要 目的分析法舒地尔对冠脉内皮细胞的的保护作用。方法选择在我院择期行PCI治疗的60例不稳定型心绞痛患者,均分为A组和B组,A组采用常规药物治疗,B组采用常规药物治疗加法舒地尔治疗,观察两组患者术前术后ROCK I,TNF-a,NO的浓度变化。结果 A、B组经PCI治疗后20 h血清ROCK I浓度、TNF-a浓度均比术前高,而且血清NO浓度较术前降低,P<0.05,差异具有统计学意义。经PCI治疗后,A组较B组浓度更高,P<0.05,差异具有统计学意义;A组较B组NO浓度下降更低,P<0.05,差异具有统计学意义。结论法舒地尔具有抑制Rho激酶,保护冠脉内皮细胞的作用。 Objective Analysis protective effect of fasudil on coronary endothelial cells.Methods Selected 60 cases of unstable angina pectoris who adopt elective PCI treatment in our hospital,were divided into the group A and the group B,the group A by routine therapy,the group B with conventional drug therapy addition fasudil,observe the two groups of patients with preoperative postoperative ROCKI,TNF-a,no concentration changes.Results After PCI treatment,the concentrations of I ROCKI and TNF-a in A and B groups were higher than those before operation,and serum NO concentrations were significantly decreased,P〈0.05,was difference had statistically significance.After treatment,the concentration of in PCI group A was higher than the group B,P〈0.05,was difference had statistically significance,the NO concentration the group A was lower than the group B,P〈0.05,was difference had statistically significance.Conclusion Fasudil can inhibit Rho kinase,protect coronary artery endothelial function.
作者 李世云
机构地区 广西医科大学
出处 《中国继续医学教育》 2016年第2期132-133,共2页 China Continuing Medical Education
关键词 法舒地尔 RHO激酶 内皮细胞 保护作用 Rho kinase Fasudil Endothelial cells Protective effect
  • 相关文献

参考文献5

二级参考文献51

  • 1阳玉霞,李惠明.高压氧治疗对脑梗塞患者的疗效分析[J].医学信息(医学与计算机应用),2014,0(22):152-152. 被引量:2
  • 2苗志林,关启刚,曾定尹.Rho激酶与动脉血管再狭窄的研究进展[J].心血管病学进展,2006,27(z1):66-69. 被引量:3
  • 3Aschermann M, Jansa P. Drug therapy of pulmonary arterial hyper- tension in 2014[J]. Vnitrni lekarstvi, 2014, 60(4) :282 -288.
  • 4Montani D, Chanmais MC, Guignabert C, et al. Targeted therapies in pulmonary arterial hypertension[J]. Pharmacol Ther, 2014, 141 (2) :172 - 191.
  • 5Macchia A, Marchioli R, Tognoni G, et al. Systematic review of trials using vasodilators in pulmonary arterial hypertension: why a new approach is needed[J]. Am Heart J, 2010, 159(2) :245 - 257.
  • 6Jiang X, Wang YF, Zhao QH, et al. Acute hemodynamic response of infused fasudil in patientswith pulmonary arterial hypertension A randomized, controlled, crossover study[ J]. Int J Cardiol, 2014, 177 (1) :61 -65.
  • 7Miyagawa K, Emoto N. A new class of drug for pulmonary arterial hypertension. Can a Rho-kinase inhibitor break the stagnation in treating it? [ J]. Circ J, 2013, 77 (10) :2477 - 2478.
  • 8Duong-Quy S, Bei Y, Liu Z, et al. Role of Rho-kinase and its inhihitors in pulmonary hypertension [ J]. Pharmacol Ther, 2013, 137(3) :352 -364.
  • 9Weir EK, Cabrera JA, Mahapatra S, et al. The role of ion channels in hypoxic pulmonary vasoconstriction[ J]. Adv Exp Med Biol, 2010, 661:3 - 14.
  • 10Rathor N, Chung HK, Wang SR, et al. Caveolin-1 enhances rapid mucosal restitution by activating TRPCl-mediated Ca2+ signaling [J]. Physiol Rep, 2014, 2(11 ):e12193.

共引文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部